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Graphical abstract 
 
 
Abstract 
The intake of fruits has proven to reduce the risk and incidence of cancer worldwide and plays a crucial role 
in cancer prevention. Pomegranate (Punica granatum), which belongs to the Punicaceae family, is one such 
plant that contains beneficial nutrients as well as many bioactive components and important phytochemicals 
that can be attributed to cancer-related therapeutic purposes. Pomegranate possesses antioxidant, anti-
inflammatory, anti-proliferative, anti-angiogenic, anti-invasive, and anti-metastatic properties, and induces 
apoptosis. It also down-regulates various signalling pathways such as NF-κB, PI3K/AKT/mTOR, and Wnt, 
and down-regulates the expression of genes that are responsible in cancer development, such as anti-
apoptotic genes, MMPs, VEGF, c-met, cyclins, Cdks, and pro-inflammatory cytokines. Therefore, inclusion 
of the fruit in one’s diet would assist in a healthy life protected from cancer and also act as an effective 
chemotherapeutic with no toxic side effects.  
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1. Introduction 
The ever increasing incidence of cancer has become the major health concern and is the second leading 
cause of death worldwide [1]. According to, GLOBOCAN 2012, 14.1 million new cancer cases are 
diagnosed annually and 8.2 million people are dying every year worldwide, while 32.6 million people are 
living and afflicted with cancer [2].The common chemotherapeutic drugs available for the treatment of 
cancer to date are associated with inconsistent clinical responses, adverse side effects, and the development 
of resistance, which ultimately leads to cancer progression and  recurrence [3, 4]. These limitations demand 
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the development of non-toxic, affordable, readily accessible, and highly effective regimens to combat this 
dreadful disease [5]. Extensive research over the past few years has revealed that an intake of a diet rich in 
fruits and vegetables is strongly linked with reduced cancer risk since they contain an abundance of 
phytochemicals with potent anti-cancerous properties [6]. Additionally, natural products generally have 
multi-targeted actions with minimal side-effects, making them ideal candidates for cancer therapeutics [7]. 
The polyphenols and flavonoid compounds present in fruits and vegetables have evinced the ability to 
downregulate the expression of various genes, proteins, and signalling cascades that are responsible for 
tumor growth and progression, making them potential therapeutic agents for cancer patients.[1, 8-10]. 
Pomegranate (Punica granatum), commonly known as grenade, granats, and punica apple, is a fruit 
belonging to the Punicaceae family and has been reported to possess profound anti-cancer properties [1, 11, 
12]. It is indigenous to the Himalayas in northern India through to Iran, parts of Southeast Asia, the East 
Indies, and tropical Africa, and grows in almost all parts of the Mediterranean region [12].  
                          The fruit is often freshly consumed and also eaten as juice, jam, and wine [1]. 
Pharmacologically, Punica granatum has been found to possess many active components that are 
antioxidant, anti-inflammatory, and neuroprotective in nature [13]. Researchers have found that the 
flavonoids obtained from pomegranate juice possess antioxidant activity similar to green tea and which is 
significantly higher than red wine [14]. Interestingly, the therapeutic potential of pomegranate has captivated 
the interest of many researchers worldwide. Furthermore, pomegranate has been shown to exhibit  
antibacterial, anti-proliferative, anti-invasive, anti-metastatic, and apoptotic properties [1, 15] The seed oil of 
pomegranate (PSO) and pomegranate peel contain many polyphenols and flavonoids that possess 
antioxidant and wound healing properties [8, 11, 16]. To understand the diverse beneficial properties of this 
plant, an extensive literature survey was conducted using Pubmed, Scopus and Google Scholar followed by 
bibliographic evaluation of the related articles published in the last sixteen years. This review focuses 
mainly on the traditional uses of the fruit, its different bioactive components, and its effect on various types 
of cancer such as bladder, breast, colon, liver, lung, prostate, skin, and leukemia, in order to provide a 
summary of research conducted to date and also to serve as criteria for further research on pomegranate.  
 
2. Traditional uses and bioactive components of pomegranate 
Pomegranate is regarded as “a Pharmacy unto itself” in Ayurveda [17]. Over the years, the seed extract, 
fruit, flower, and leaves of Punica granatum have been known to prevent thyroid disorders and thickening 
of arteries due to their potent anti-inflammatory, antioxidant, and cardioprotective function, and to prevent 
degenerative diseases [17, 18]. In traditional medicine, the seed of the plant has been found to improve 
urination and prevent urinary diseases [17]. In Unani and Chinese medicine, pomegranate has been 
documented for the management of diabetes [19]. Numerous findings have also reported the use of 
pomegranate as the herbal medicine of choice for the treatment of diabetes and renal disorders [20, 21]. 
Different plant parts of pomegranate have been outlined for their application in various folklore medicines 
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for their therapeutic ability in the treatment of diverse pathological diseases [22]. The pomegranate fruit has 
been used for the treatment of acidosis, dysentery, microbial infections, diarrhea, helminthiasis, hemorrhage, 
and respiratory diseases.  
                     It is also known to exhibit anti-viral activity against herpes virus and influenza virus [23]. It has 
been used extensively as an astringent, hemostatic, and antimicrobial agent in Iranian traditional medicine 
[24]. The rind powder helped in the treatment of periodontitis and possesses antihelmintic properties [25, 
26]. In traditional medicine, pomegranate seed has been reported to regulate urine discharge and control the 
burning sensation of urine, and been used for the treatment of bronchitis, diarrhea, digestive problems, 
infected wounds, and diabetes [17, 24]. In Mauritian folklore, bark extracts of the plant have been used to 
cure asthma, chronic diarrhea, chronic dysentery, and intestinal worms [22]. Moreover, the peel of 
pomegranate fruit is known for its strong astringent and anti-inflammatory properties as well as being a 
therapy for traumatic hemorrhage, ulcers and infections, diarrhea, dysentery, dental plaque, and as a douche 
and enema agent [25, 27]. The water decoction of the fruit has been used for the treatment of aphthae and 
ulcers in India, Tunisia, and Guatemala [27]. The peel has also found enormous application in traditional 
Chinese medicine for its efficacy in promoting hemostasis, killing parasites, and overcoming hyperacidity, 
along with potent wound healing abilities, therapy of diabetes, cancer, and blood pressure control [11, 25, 
28]. In addition, studies have found that pomegranate peel impeded the release of toxins by bacteria and 
aided in their reduced growth [24].  
                      Punica granatum has been considered to be pharmacologically active due to the presence of 
abundant phytochemicals [29, 30]. The different parts of the plant consist of various chemical compounds 
that impart crucial roles in the prevention of many diseases [25]. Different classes of phytochemicals have 
been identified from pomegranate, such as ellagitannins, gallotannins and derivatives, flavonoids, lignins, 
triterpenoids and phytosterols, fatty acids and lipids, organic acid and phenolic acids [30]. The fruit parts 
such as peel, aril, seeds, and juice are rich in phenolic acids, flavanols, flavones, flavonones, anthocyanidins, 
and anthocyanin [25, 30]. Glycated anthocyanins such as pelargonidin 3, 5-diglucoside and pelargonidin 3-
glucoside are present in the pomegranate flower, while the leaves, roots, and stem contain apigenin, 
punicalin, punicalagin, and luteolin [25]. The fruit and its pericarp contain phenolic compounds, tannins, and 
hydrolysable tannins [24]. Pomegranate is a rich source of polyphenols [31, 32]. Especially, the 
pomegranate peel contains a larger amount of  the polyphenol known as punicalagin, which is an 
ellagitannin with antioxidant efficacy and is unique to pomegranate [1]. 
                  Furthermore, compounds such as corilagin and pseudopelletierine have been obtained from the 
pomegranate peel and have been found to exert anti-tumor properties [28]. Large amounts of polyphenols 
such as  ellagic acid (EA), gallotannins, anthocyanins (3-glucosides and 3, 5-glucosides of delphinidin, 
cyanidin, and pelargonidin), catechins, and other flavonoids (quercetin, kaempferol, and luteolin 
glycosides), gallocatechins, phenolic acids, tannins (punicalin and punicafolin), and punicalagin (PC), 
flavone glycosides, apigenin, sitosterol, fatty acids, and volatile compounds have also been found to be 
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present in pomegranate juice [Figure 1] [1, 12, 33-37]. Punicic acid (PuA) is a conjugated linolenic acid 
(C18:3Δ9c, 11t, 13c) with a wide range of nutraceutic effects and is the main component of seed oil from 
Punica granatum [38]. The conjugated fatty acid (cis(c)9, trans(t)11) and polysaccharide (PSP001) were 
obtained from seed oils and fruit rind of pomegranate respectively[39, 40].Galactomannan (PSP001) 
obtained from the fruit rind of Punica granatum has been reported as an excellent antioxidant, 
immunomodulatory, and anti-cancer agent [41]. Therefore, it would be important to discuss the potent 
effectiveness of the different therapeutic compounds isolated from the plant in the treatment and prevention 
of various cancer types.  
 
3. Molecular targets modulated by Punica granatum  
The rich content of phytochemicals in the plant has assisted in the treatment of various cancer types. 
Numerous studies have reported the potent chemotherapeutic properties of Punica granatum that has 
targeted many molecular pathways and gene expression [Figure 2 & Table1]. EA and PSO extracts induced 
cell cycle arrest in the G0/G1 phase, the PLE induced G2/M phase arrest, and the acetonitrile fraction 
obtained from the pomegranate juice induced S phase arrest in several types of cancers.[42-45]. Different 
studies have found that treatment with pomegranate extract led to regulation in the expression of cyclin-
dependent kinase (cdk) inhibitors WAF1/p21 and KIP1/p27 [46-48]. Moreover, it was found to be 
associated with the significant down-regulation of cyclins D1, D2, E, cyclin-dependant kinase (cdk)2, cdk4, 
and cdk6 that are noted to be the important regulators of the cell cycle [46, 49-51]. The expression of pro-
inflammatory cytokines such as Interleukin (IL)-1β, IL-2, IL-6, IL-8, IL-12, IL-17, induced protein 10 (IP-
10), Macrophage Inflammatory Protein (MIP)-1α, MIP-1β, monocyte chemoattractant protein (MCP)-1, 
Tumor necrosis factor (TNF)-α, and Regulated on Activation, Normal T Expressed and Secreted (RANTES) 
was considerably reduced with the treatment of PSO extract in breast cancer in a dose-dependent manner  
[45, 52, 53]. These pro-inflammatory cytokines are produced predominantly by activated macrophages and 
are involved in the up-regulation of inflammatory reactions [54]. Additionally, the intake of pomegranate 
juice (PJ) leads to inhibition of the expression of α-induced Cyclooxygenase-2 (COX-2) in colon 
tumorigenesis [55]. 
                                   Pomegranate extract has been found to down-regulate the increased expression of 
inflammatory markers such as inducible nitric oxide synthase (iNOS), 3-nitrotyrosine, heat shock protein 
70(HSP70) and 90, and Nuclear Factor Kappa Beta (NF-κB) in a dose-dependent manner [56]. It also 
decreased the phosphorylation of PI3K/AKT (i.e. halted the phosphorylation of Akt at Thr(308)), suppressed 
the mechanistic target of rapamycin (mTOR) signaling pathway, and up-regulated  Jun N-terminal Kinase 
(JNK) phosphorylation [50, 57-61]. Moreover, in in vivo studies, pomegranate emulsion (PE) reduced the 
expression of COX-2 and HSP90, and halted IκBα degradation; thereby inhibiting the translocation of NF-
κB from the cytosol to nucleus. However, a rise in nuclear factor erythroid 2p45 (NF-E2)-related factor 2 
(Nrf2) expression and nuclear translocation was observed in 7, 12-dimethylbenz[a]anthracene (DMBA)-
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induced mammary tumorigenesis [62, 63]. In addition, the up-regulation in expression of growth factors 
such as vascular endothelial growth factor (VEGF) and c-met was reduced, and it also modulated the 
transforming growth factor beta (TGF-β)/Smads pathway [45, 64]. Chen HS et al., reported the TGF-
β/Smad signaling pathway as the molecular target of Ellagic acid (EA), which promoted cell cycle arrest in 
breast cancer cells in vitro [44].TGF-β1-induced arrest occurs during G1 and is mediated by Smad proteins, 
which regulate transcriptional targets, including c-myc [44]. The inhibition in the expression of c-myc led to 
the suppression of Cdk4-cyclin D [44].  
                         Dong Y et al., have revealed that the combined over-expression of cyclin D1 and Cdk4 in 
cancer patients indicates the poorest overall survival [65]. It has been demonstrated that treatment with 
pomegranate extracts caused a reduction in oxidative stress and regulated the expression of miR-126 [57, 
58]. Also, a study carried on prostate cancer cells reported that microRNAs such as miR-335, miR-205, and 
miR-200 (that are anti-invasive) were increasingly expressed, while miR-21 and miR-373 (that are pro-
invasive in nature) were suppressed following treatment with pomegranate extracts [53]. The β-catenin 
pathway was also inhibited via the suppression of β-catenin and its downstream factors  cyclin D1 and 
survivin [66]. Moreover, punicalagin treatment led to the up-regulation of tissue inhibitor of 
metalloproteinase (TIMP)-2 and TIMP-3, and lessened the activities of matrix metalloproteinase (MMP)-2 
and MMP-9, thereby retarding the migration of ovarian cancer cells [66]. It has also been shown in 2-
dimethylhydrazine-induced colon cancer that treatment with standardized pomegranate extract reduced the 
Wnt pathway activity by down-regulating Wnt5a, FRZ-8, b-catenin, Lef1, Tcf4, c-myc, and cyclin D1. 
Remarkable up-regulation in the expression of APC and axin1 in the tissue occurred with diminution in the 
level of carcinoembryonic antigen (CEA) in the serum [49].  
                Studies with DNA microarrays have found that pomegranate extract suppresses the genes related 
to chromosome architecture, mitosis, DNA replication, processing of RNA, and repairing of damaged DNA; 
however, increased expression of apoptotic genes was observed in several types of cancer. Decreased 
expression of genes such as MRE11, RAD50, NBS1, RAD51, BRCA1, BRCA2, and BRCC3 that are 
responsible for the double strand break (DSB) repair via homologous recombination (HR) was also seen 
[67]. It also raised the levels of p21 and p53 and increased the expression of caspases and cytochrome c, 
thereby leading to apoptosis [68]. The proteolytic activity of collagenase IV, which plays a main role in 
proteolysis of tumor cell-mediated extracellular matrix, was found to be considerably decreased by treatment 
with EA [52, 69]. Other reports have indicated that pomegranate extract can reduce the expression of MMP-
2 and MMP-9 and lowered the levels of reactive oxygen species (ROS) and the mitochondrial membrane 
potential [43, 50, 59]. Experimental studies on DU145 and PC3 prostate cancer cells have shown that PJ 
increased the expression of E-cadherin and intercellular adhesion molecule 1 (ICAM-1) that took part in cell 
adhesion, while  genes such as hyaluranan-mediated motility receptor (HMMR) and type I collagen involved 
in cell migration were poorly expressed [53]. Also, mRNA and protein expression of vascular cell adhesion 
molecule 1 (VCAM-1) was found to be down-regulated by the polyphenolic compounds of pomegranate 
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[58]. Wang L et al., have reported that PE suppressed the migration and chemotaxis of prostate tumor cells 
towards stromal cell-derived factor 1α (SDF1α), a chemokine crucial for metastasis of tumor cells to bone 
[70]. The PJ effectively impeded the activity of SDF1α, a chemokine whose receptor is CXCR4, and 
inhibited cancer cell metastasis towards the bones [53]. Further, Sahebkar and group performed two meta-
analyses of randomized controlled trials to evaluate the effect of PJ on plasma C-reactive protein (CRP) 
concentrations and lipid profile. The results indicate that consumption of PJ did not cause any notable effect 
on plasma CRP levels as well as lipid profile in human [71, 72] 
 
4. The effect of pomegranate on different types of cancer 
An abundance of studies has clearly demonstrated pomegranate to exert anti-cancer properties against 
diverse cancer types.  
 
4.1 Pomegranate and bladder cancer 
Bladder cancer is one of the widespread lethal malignancies of the urinary tract, with poor outcomes for 
patients with advanced stages of disease [73, 74]. Pomegranate is known to be a functional food of great 
significance, owing to its numerous health benefits in humans, and has been found to play a crucial role in 
the treatment of bladder cancer [18, 75]. Lee ST et al., reported that pomegranate fruit ethanol extract (PEE) 
suppressed the proliferation of UBUC tumor cells via cell cycle arrest at S phase due to up-regulation of 
cyclin A and down-regulation of cdk-1 [75]. Further, it was seen that PEE triggered pro-caspase-3, -8, and-
9, and elevated the Bax/Bcl-2 ratio. Above all, it was also found that PEE stimulated the expression of 
procaspase-12, with increased expression of CHOP and Bip, which are endoplasmic reticulum (ER) stress 
markers [75]. Additionally, Wu TF et al., demonstrated that ethanol extract possesses anti-proliferative and 
apoptotic activities by down-regulating the PTEN/AKT/mTORC1 pathway through increased expression of 
profilin 1 [73]. 
 
4.2 Pomegranate and breast cancer 
Breast tumor-associated mortality ranks second among women in the world and is found to be more 
prevalent in less developed regions [44]. In the year 2012, around 1.67 million new cases were diagnosed, 
i.e. 25% of all cancers [2]. Pomegranate has been proven to be a promising therapeutic agent against breast 
tumors [76]. Experimental studies have found that PJ and its components such as luteolin, EA, and punicic 
acid (PA) enhance the adhesion of tumor cells by up-regulation of E-cadherin and diminished tumor cell 
migration, without affecting the normal cells.  It also suppressed the expression of pro-inflammatory 
cytokines IL-8, RANTES, and PDGFB, and obstructed chemotaxis of tumor cells to the chemokine SDF1α 
[76]. EA exhibited growth inhibitory effects against breast cancer cells by inducing cell cycle arrest in the 
G0/G1 phase via the TGF-β/Smads pathway [44]. Resveratrol, a phytoestrogen present in pomegranate, has 
been found to be an effective agent against breast tumor progression and metastasis, and helped in the 
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chemosensitization of breast tumor cells to different chemotherapeutic drugs by inducing apoptosis and 
inhibiting aromatase activity [77]. Ellagitannins obtained from pomegranate have also shown estrogen-
responsive breast tumor preventive characteristics via anti-aromatase activity, thereby inhibiting 
testosterone-induced proliferation of MCF-7 cells. This aromatase enzyme has been found to play a crucial 
role in tumorigenesis and takes part in the conversion of androgen to estrogen [78, 79]. 27-
hydroxycholesterol (27HC), an endogenous selective estrogen receptor (ER) modulator (SERM), which is a 
primary metabolite of cholesterol and an ER and liver X receptor (LXR) ligand, has been found to be 
responsible for ER-dependent growth in breast cancer [80, 81]. The methanolic extract of the pomegranate 
pericarp (PME) down-regulated the activity of 27HC and led to reduced cell growth and proliferation of 
breast cancer cells.  
                  Furthermore, PME was found to be associated with the ER and caused abrupt expression of 
estrogen response elements (ERE) [81]. It has also been reported that PME suppressed ER-positive breast 
tumor growth and proliferation via SERMs [82]. PSP001, a polysaccharide obtained from the pomegranate 
fruit rind, inhibited the rate of cell growth and proliferation, and the PPE extract caused apoptosis in MCF-7 
cells [31, 40, 83, 84]. Treatment with 40 µM punicic acid has been found to cause cell death by 86 and 91% 
in MDA-MB-231 and MDA-ERalpha7 cells respectively [85]. In MCF-10A and MCF-7 cells, inhibition of 
VEGF and increased expression of migration inhibitory factor (MIF) was seen when treated with PSO and 
fermented pomegranate juice [86]. Kim ND et al., reported that the PSO extract suppressed MCF-7 cell 
proliferation of by 90% at 100 µg/ml and cell invasion by 75% at 10µg/ml. Also, it was found to induce 
54% apoptosis at 50µg/ml in MDA-MB-435 cells, which are estrogen receptor negative metastatic breast 
cancer cells [87]. It has been evidenced that PE showed cytotoxicity, suppressed proliferation, and elevated 
caspase-3 enzyme expression of WA4 cells in vitro [88]. Another study showed that the hydrophilic fraction 
of 80% aqueous methanol extract obtained from PSO led to significant reduction in cell growth, with cell 
cycle arrest at G0/G1 phase in two breast cancer cell lines- MCF-7 and MDA MB-231. Also, an increased 
expression of growth factors and pro-inflammatory cytokines was considerably reduced in a dose-dependent 
manner [45].  
                           Moreover, experimental studies have shown that pomegranate fruit extracts (PFEs) down-
regulated the expression of NF-kB-dependent reporter gene and reduced the levels of RhoC and RhoA, 
thereby inhibiting metastasis of breast tumor cells [89]. In DMBA-induced mammary tumorigenesis in rats, 
pomegranate phytochemicals showed remarkable anti-proliferative and pro-apoptotic activities, thereby 
inducing a chemopreventive effect. A decreased expression of the intra-tumor ER-α, ER-β, and ER-α: ER-β 
ratio was also observed following treatment with a pomegranate emulsion. It also down-regulated β-catenin 
expression (a transcriptional cofactor for Wnt signaling), and cyclin D1, which is involved in the regulation 
of cell growth [90]. Further in vivo studies showed a decreased development of cancerous lesions by 47% 
following treatment with the polyphenols obtained from pomegranate fermented juice in DMBA-induced 
tumor lesions in the murine mammary gland [87, 91]. Interestingly, the nanoencapsulation of PC and EA 
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inhibited cell proliferation by 2- to 12-fold in MCF-7 and Hs578T breast cancer cells and increased the anti-
tumor activity of the compounds [92]. The PSO extract showed a synergistic effect with trans-resveratrol in 
a self-nanoemulsifying drug delivery system (RES SNEDDS). In vitro studies have found that RES 
SNEDDS-PSO has a remarkable inhibitory effect against MCF-7 breast cancer cells [93]. It has also been 
found that the mono-dispersed gold nanoparticles synthesized with pomegranate fruit peel extract (PAuNPs) 
improved the therapeutic potential of Fluorouracil and targeted drug delivery [94].  
 
 
4.3  Pomegranate and colon cancer 
Colorectal cancer (CRC) is the leading cause of death globally. Approximately 70% of CRC cases are 
known to be sporadic and almost all are associated with a sedentary lifestyle [95]. Epidemiological studies 
have indicated that the intake of pomegranate has an inverse correlation with colon cancer incidence [95]. 
Pomegranate has been noted for its anti-tumorigenic properties in the colon [89]. Experimental studies on 
the HT-29 human colon cancer cell line have shown that the intake of PJ at a concentration of 50 mg/L 
resulted in 79% inhibition of TNFα-induced COX-2 protein expression [55]. In vitro studies have shown 
that PC, EA, and total pomegranate tannin extract possessed antioxidative properties and were found to 
induce apoptosis and reduce cell growth in HT-29 and HCT116 colon cancer cells [96].  
                       Also, it has been reported that the ellagitannins obtained from pomegranate are hydrolyzed to 
form EA and are transformed to urolithin by gut microbiota. These components were found to impede Wnt 
signaling [97]. It has been evidenced that EA caused cell death in Caco-2 colon cancer cells but not in CCD-
112CoN normal colon cancer cells [98]. In vivo studies have shown that treatment of azoxymethane (AOM)-
induced tumorigenesis in rat colon with PPE mitigated cytotoxic activities [99]. The PSO inhibited AOM-
induced colon tumorigenesis due to the up-regulation of PPARγ protein expression [100]. Additionally, 
there are evidences that PJ, PPE, and PSO induced anti-tumorigenic activity against colon malignancies and 
reduced the number of aberrant crypt foci (ACF) and premalignant lesions developed in AOM-induced 
colon cancer [57, 58, 101].  
 
4.4 Pomegranate and leukemia 
Leukemia, a cancer of the blood and bone marrow, has been divided into four types on the basis of cell type 
and growth rate to give the categories of acute lymphocytic, chronic lymphocytic, acute myeloid, and 
chronic myeloid leukemia [102]. Pomegranate has been found to exert anti-cancer properties against 
leukemia. Treatment with PPE caused growth inhibitory effects and apoptosis in K562 cells, which were 
mediated by G2/M cell cycle arrest. It also raised the levels of p21 and p53 and increased the expression of 
caspases and cytochrome c, thereby leading to apoptosis [68]. The acetonitrile fraction obtained from PJ has 
been found to lower the levels of ATP in leukemia, with considerable up-regulation of caspase-3 and 
morphological alterations in the nucleus [42]. Another study has shown that a polysaccharide, PSP001, 
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separated from pomegranate, reduced the proliferative rate of chronic myeloid leukemic cells [40]. The 
compound has also been found to be non-toxic and augmented the growth of normal lymphocytes in vitro 
[40]. Moreover, the fermented juice and PME lowered the rate of tumor growth and proliferation of HL-60 
cells in vitro [103]. Contrastingly, nanoparticles synthesized from partially purified pomegranate 
ellagitannins with gelatin were found to exert no impact on the apoptosis of HL-60 leukemia cells [104]. 
 
4.5 Pomegranate and liver cancer 
Globally, hepatocellular carcinoma (HCC) has been noted as the fifth commonly widespread cancer and 
third foremost reason for cancer associated deaths, with limited treatment modalities [105]. Oxidative stress 
has been identified as the main driving force behind the occurrence of this cancer type [63]. Pomegranate is 
known to possess potent antioxidant and anti-inflammatory properties due to the presence of diverse 
beneficial phytochemicals [56, 63]. In the study conducted by Bishayee A et al., 2011, it was observed that 
when pomegranate emulsion was used to treat dietary carcinogen diethylnitrosamine (DENA)-induced rat 
carcinogenesis in the liver, it resulted in marked diminution in the incidence, number, multiplicity, size, and 
volume of hepatic nodules, which are known to be the potent precursors of hepatic carcinoma [63]. This 
inhibition of hepatocarcinogenesis was found to be mediated through modulation of the NF-κB signaling 
pathway [56].  
          It has been experimentally proven that treatment with pomegranate hull extract on DENA-induced 
HCC reduces the size of the tumor. In addition, it has been found to down-regulate the expression of cyclin 
D1 and β-catenin, which suggested that pomegranate could be a potent anti-cancerous therapeutic agent 
[105]. Pomegranate peel polyphenols (PPPs) induced cell arrest at the S-phase, increased the number of 
apoptotic cells, the levels of ROS and Cyt-c, and Caspase-3/9 activity. In addition, the Bax/Bcl-2 ratio and 
the protein expression of p53 were also up-regulated [106]. Celik I et al., have reported that the beverage of 
pomegranate has antioxidant and protective effects against carcinogenic chemical (trichloroacetic acid) 
induced oxidative injury in rats [107]. Studies have also found that silver nanoparticles (AgNPs) using a 
Punica granatum leaf extract (PGE) reduced cell growth and proliferation of HepG2 cells. Additionally, 
PGE-AgNPs showed in vitro free radical-scavenging and antioxidant activity [108]. 
 
 
4.6 Pomegranate and lung cancer 
Lung cancer has been noted as the most prevalent cancer worldwide, with around 1.8 million new cases in 
the year 2012 [2]. It has been demonstrated that PPE and seed extract possessed antioxidant properties and 
inhibited the growth and proliferation of A549 cells in vitro [31, 109]. The treatment of a non-small cell lung 
carcinoma cell line with pomegranate leaf extract (PLE) inhibited cell invasion and migration via cell cycle 
arrest at the G2/M phase, reduced the expression of matrix metalloproteinase, and lowered ROS and the 
mitochondrial membrane potential [43, 50, 59]. Both in vitro and in vivo studies have found that treatment 
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with PFE led to the down-regulation of NF-κB expression and suppressed the degradation and 
phosphorylation of I-κBα kinase. It also suppressed MAPK phosphorylation, and inhibited PI3K activity and 
phosphorylation of Akt at Thr(308). Moreover, it inactivated the mTOR pathway, inhibited c-met 
phosphorylation, and lowered the expression of CD31 and VEGF [50, 59]. PSO has also been found to be 
cytotoxic and reduced the rate of cell proliferation of A549 cells [109]. DNA cell cycle analysis found that 
PFE treatment caused cell cycle arrest at the G0-G1 phase, regulated the expression of cdk 2, cdk4, cdk6, 
WAF1/p21, and KIP1/p27, and reduced the expression of cyclins D1, D2, and E [50]. Altogether, these 
studies suggest that pomegranate has potent chemotherapeutic properties that exert anti-cancerous activities 
on lung carcinoma by inducing apoptosis, inhibiting cell growth and proliferation, and thereby impeding the 
migration and progression of lung cancer.  
 
4.7 Pomegranate and prostate cancer 
Prostate cancer is the second leading cause of death among men [110]. In vitro studies have found that PFE 
and EA regulated the expression of pro-apoptotic genes Bax and Bak in prostate tumor cells, thereby 
inducing apoptosis via an increase in the Bax/Bcl-2 ratio. Furthermore, the expression of WAF1/p21 and 
KIP1/p27 was found to be up-regulated while the anti-apoptotic genes Bcl-X (L) and Bcl-2 were down-
regulated. Moreover, it also reduced the expression of cyclins D1, D2, and E, and cyclin-dependent kinases 
cdk2, cdk4, and cdk6 [46-48]. An in vivo study using the transgenic rat for adenocarcinoma of prostate 
(TRAP) model showed that both PJ and EA inhibited the growth, proliferation, and progression of prostate 
tumor, thereby promoting apoptosis via increased caspase 3 expression [46]. PJ and its components EA, L, 
and PA have been found to significantly suppress the growth of prostate tumor [46, 70]. The combined 
administration of L, EA, and PA suppressed hormone-dependent and –independent tumor cell proliferation 
and migration. It also inhibited metastasis by down-regulating chemotaxis towards the chemokine CXCL12. 
The components altogether controlled angiogenesis in in vivo conditions, down-regulated IL-8 and VEGF 
expression, and hindered the progression as well as metastasis of PCa cells [64]. In another study, 
pomegranate extract has found to minimize the protein levels of HIF-1alpha and VEGF, thereby reducing 
the tumor size and vessel density in vivo [111]. EA suppressed the level of MMP-2, reduced cell viability, 
and halted tumor cell invasion of nearby tissues [52].  
                Further experimental studies on prostate cancer cells have reported the remarkable inhibition of 
cancer progression due to the reduced expression of IL-6, IL-12p40, IL-1β, and RANTES [53]. PE enhanced 
the phosphorylation of JNK, down-regulated the Akt and mTOR pathways, and inhibited NF-κB activation 
[60, 61] Upon treatment with punicic acid, a decreased growth rate of the androgen-dependent LNCaP cells 
was observed, together with increased apoptosis [112]. In addition, PC remarkably scavenged 2, 2-diphenyl-
1-picryhydrazyl (DPPH) and inhibited lipid peroxidation (LPO) in PC-3 and LNCaP cells in a 
concentration-dependent manner. Also, up-regulation in the expression of caspases-3 and -8 was observed in 
PC-3 [113]. Seeram NP et al., have reported that the bioactive metabolites urolithins and ellagic acid, 
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obtained from pomegranate, were found to suppress tumor growth in vitro. Moreover, an in vivo study has 
reported high levels of metabolites in the prostate gland and proved that PE considerably suppressed LAPC-
4 xenograft growth in SCID mice [114]. Additional reports have shown that EA and urolithin A (UA) 
promoted cell cycle arrest in the S and G2/M phase respectively, accompanied by a decline in the levels of 
cyclin B1 and D1, and induced apoptosis in EA treated prostate tumor cells. However, UA treatment showed 
dysregulation of the cyclin B1/cdc2 kinase complex via elevation of cyclin B1 and phosphorylated cdc2 
[115]. Ming DS et al., showed that the treatment of prostate tumor cells with 0-12μg/mL of pomegranate 
extract lessened the synthesis of testosterone, DHT, DHEA, androstenedione, androsterone, and 
pregnenolone [116]. Further, in vivo studies found a diminution of serum steroid levels [116].  
                In another study, Hong MY et al., found that pomegranate polyphenols retarded the expression of 
genes linked with the enzymes producing androgen and the androgen receptors (AR), which are up-
regulated in androgen-independent prostate tumor cells [117]. Wang Y et al., reported the efficacy of 
pomegranate extract in inducing cytotoxicity and suppressing survival of metastatic castration-resistant PCa 
cells [118]. Studies have revealed survivin as a novel molecular target that regulated the anti-tumor activity 
of pomegranate extract via suppression of STAT3 [118]. In vivo studies have also found that pomegranate 
extract suppressed the expression of survivin, induced apoptosis, retarded C4-2 tumor growth in the 
skeleton, and significantly improved the effect of docetaxel in athymic nude mice [118]. Pomegranate peel 
extract (PoPx) showed inhibition of migration and invasion of the prostate cancer cells via a reduced level of 
MMP2/MMP9 and increased TIMP2 expression [119].  
                  Furthermore, loss of mitochondrial transmembrane potential (Δym), an increase in ROS and 
Bax/Bcl2 ratio, and activation of caspase-3 occurred, leading to apoptosis of the prostate tumor cells [119]. 
Moreover, pomegranate whole seed ethanolic extract (PSEE) contains punicic, α-linoleic, and α-linolenic 
acids, which increased the inhibition of cell growth in the hormone dependent LNCaP prostate tumor cell 
line [120]. Overall, the different compounds obtained from pomegranate were found to exert anti-
proliferative activity and anti-angiogenic effects, and induced apoptosis in prostate cancer. Hence, 
pomegranate can be regarded as an effective chemotherapeutic agent for the treatment of prostate cancer.  
 
4.8 Pomegranate and skin cancer 
Skin cancer is a widespread cancer, as skin serves as the first line of defence against heat, sunlight, injury, 
and infection [121]. Several in vivo studies have revealed that pomegranate possess anti-skin tumor 
promoting properties in various animal models [122, 123]. PFE has been observed to suppress UVB 
radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis [124]. It has been found to inhibit skin 
edema, hyperplasia, lipid peroxidation, hydrogen peroxide generation, ornithine decarboxylase (ODC) 
activity, COX-2 expression, and expression of proliferating cell nuclear antigen. In addition, repair of UVB-
mediated development of cyclobutane pyrimidine dimers and 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-
oxodG) was enhanced considerably [124]. Studies have found that PFE and diallyl sulfide synergistically 
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reduced the tumor incidence and caused regression in tumor volume in a 2-stage mouse skin tumorigenesis 
model due to down-regulation in the expression of ERK1/2 and JNK1, and a decrease in NF-κB/p65 
expression [125]. Moreover, increased expression of the tumor suppressor p53 and cyclin kinase inhibitor 
p21 was observed along with the down-regulation of NF-κB and IKKα, together with inhibition of the 
phosphorylation and degradation of IκBα [124, 126]. PFE also suppressed UVB-mediated phosphorylation 
of MAPK and inhibited p38 protein expression [126]. Another in vivo study by Hora JJ et al., has shown that 
5% pomegranate seed oil considerably reduced the expression of 12-O-tetradecanoylphorbol 13-acetate 
(TPA)–induced ODC activity that assists in skin cancer promotion [122]. Overall, pomegranate has been 
found to possess potent, efficacious chemopreventive properties against skin cancer while demonstrating no 
adverse side effects. 
 
4.9 Pomegranate and other cancers 
Pomegranate is known for its multiple health benefits and the possession of anti-cancerous properties. It has 
been shown that the polyphenolic-rich extracts of the non-edible parts of Punica granatum, such as leaves, 
stem, and flower extract, elicit anti-proliferative and apoptotic effects, with a rise in loss of mitochondrial 
membrane potential and cell cycle arrest, and reduced expression of MMP in U266 multiple myeloma cells 
[127]. Moreover, PJ showed anti-proliferative and anti-angiogenic properties and induced cell cycle arrest at 
the G0/G1 phase in multiple myeloma cells [128]. Ellagic acid obtained from the pomegranate peel extract 
was found to inhibit Hela cell invasion via suppression of the AKT/mTOR signaling pathway due to 
augmentation in the level of IGFBP7 expression [129]. Experimental studies have shown that PPE and the 
seed extract also inhibit the growth and proliferation of SKOV3 ovarian cancer cells [31, 109]. In addition, 
punicalagin has been found to inhibit cell proliferation and induce cell cycle arrest at the G1/S phase, thereby 
promoting apoptosis via up-regulation of Bax and down-regulation of Bcl-2 expression [66]. Nair V et al., 
demonstrated that PE altered the cell phenotype by elevating the proportion of cells deficient in the 
expression of CD44 and CD24. PE was also found to be highly efficacious in suppressing the rate of cell 
proliferation of PANC-1 and AsPC-1 pancreatic cells, as compared to the dose of paclitaxel prescribed 
clinically [130]. Further investigations concluded that ellagic acid, luteolin, and ursolic acid are the 
compounds that were responsible for the decreased cell proliferation of PANC-1 cells in a dose-dependent 
manner [130].  
 
5. Clinicopathological studies of pomegranate on cancer 
Several clinical trials have been performed in recent years on the anti-cancerous properties of pomegranate 
in colon and prostate cancer [97, 131]. Studies have shown that pomegranate juice possesses protective 
properties against prostate cancer [131]. A 14.7% rise in the median levels has been observed for prostate-
specific antigen (PSA) in the patients who received a food supplement consisting of pomegranate, which is 
rich in polyphenol [132]. Pomegranate juice, extracts, and whole fruit powder were usually given for the 
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treatment of patients suffering from prostate cancer [131, 133-135]. Pantuck et al., first reported on clinical 
trials in prostate cancer patients where elongation in the PSA doubling time (PSADT) was observed after 
treatment with PJ [133]. PSA has been reported to be the earliest biomarker of serum for the diagnosis of 
prostate cancer [136]. In a randomized phase II study, patients with prostate cancer were given 1 or 3 g of 
PE, which caused a reduction in PSA in 13% of the patients, while in 43% of patients, an elevated PSADT 
was observed in the two arms, with no significant side effects. Although little toxicity was observed, some 
patients were found to suffer from diarrhea [137]. On the contrary, Pantuck et al., reported that PJ did not 
show any significant increase in PSADT as compared to placebo, as suggested by their placebo-controlled 
study [134]. A study using PE on colorectal cancer patients also found the presence of urolithin bioactive 
metabolites at a dose of 900 mg/day for 15 days [97]. These metabolites are synthesized by the gut 
microbiota and have been found to exert anti-cancer properties [138]. However, in a clinical study of 70 
patients before radical prostatectomy, the oral administration of two tablets of PE or placebo for four weeks 
showed no dissimilarities between both arms of the study [135]. 21 of the 33 patients in the PE treated group 
and 12 of the 35 in placebo group showed the presence of UA glucuronide. In addition, no differences in the 
regulation of pS6 kinase, NF-κB, Ki67, and PSA levels were observed in the two cohorts [135]. [Table 2] 
 
6. Conclusion 
Traditionally, pomegranate has been used by people worldwide for various medicinal applications. It has 
been found to be a potent anti-cancer agent that contains many bioactive components such as ellagic acid, 
punicic acid, and punicalagin. The extracts obtained from this plant have been found to suppress tumor cell 
proliferation, and induce cell cycle arrest and apoptosis through modulation of various transcription factors, 
signaling pathways, and the expression of various genes in both in vitro and in vivo settings. Clinical studies 
reported pomegranate juice intake aids in the control and stabilization of prostate and colon cancer. 
However, very few clinical studies have been undertaken. Therefore, more clinical studies are required to 
elucidate the diverse therapeutic properties of pomegranate and to establish it as an effective therapeutic 
strategy for the successful prevention and treatment of cancer. 
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Figure 2: Molecular targets of Punica granatum 
 
Figure 2: Structures of different compounds isolated from pomegranate 
 
Table 1: The effect of Punica granatum on different types of cancer (Preclinical studies) 
Table 2: Studies on the potential of Punica granatum in the prevention and treatment of cancer (clinical 
studies) 
 
 
Table 1: The effect of Punica granatum on different types of cancer (Preclinical studies) 
-------------------------------------------------------------------------------------------------------------------------------------------------------------
Cancer  Model        In vitro / Effect      Reference 
     In vivo / 
     Clinical 
------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Bladder cancer  
T24 cells      In vitro Inactivated PTEN/AKT/mtorc1 pathway via  [73]  
profilin 1  
EJ cells       In vitro Increased expression of p53 protein and miR-34a [139]  
T24 and J82 cells      In vitro Reduced cell growth via cell cycle arrest at S phase  [75]   
DMBA-initiated       In vivo Reduced the expression of COX-2 and HSP90 [62] 
 rat mammary tumor 
MCF-7, MDA-MB-231      In vitro Reduced the ERE- mediated transcription  [81] 
 MCF-7        In vitro Inhibited cell proliferation    [109] 
  DMBA-inflicted rat       In vivo Reduced the expression of intra-tumor ER-α and [90] 
ER-β, lowered  
  DMBA-induced rat      In vivo Up-regulation of Bad, caspase-3, caspase-7,  [140] 
caspase-9, poly (ADP ribose) polymerase, and cyt- c  
  MCF-7        In vitro Inhibited proliferation of tumor cells   [31] 
  MCF-7        In vitro Targeted TGF-β/Smads signaling pathway      [44]   
  MCF-7         In vitro Reduced the rate of proliferation of tumor cells [120]   
MCF-7, MDA-MB-231      In vitro Reduced VEGF and nine pro-inflammatory   [45] 
cytokines (IL-2,IL-6, IL-12, IL-17, IP-10, MIP-1α,  
MIP-1β, MCP-1, and TNF-α)   
  MCF-7        In vitro Inhibited tumor cell proliferation   [141] 
  MCF-7        In vitro Inhibited tumor growth via cell cycle arrest at G2 /M [67] 
  MCF-7, MDA-MB-231      In vitro Reduced pro-inflammatory cytokines/chemokines [76] 
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  MDA-MB-231       In vitro Lowered Sp proteins and Sp-regulated genes  [58] 
  BT474 xenograft mice      In vivo Promoted expression of SHIP-1, reduced 
miRNA-155, and impeded PI3K-dependent 
phosphorylation of AKT 
  MCF-7        In vitro Reduced tumor cell proliferation   [40] 
  MCF-7        In vitro Increased expression of Bax, decreased expression  [83] 
of Bcl-2   
  MCF-7, MDA MB-231      In vitro Reduced the expression of selected estrogen- [82] 
responsive genes    
                             HCC1806, MDA231,      In vitro Inhibited cell growth and reduced MAPK signaling [142]  
MDA468, MDA453, 
SKBR3, BT474, MCF7 
WA4        In vitro Decreased cell growth and cell viability  [88]   
MCF-7        In vitro Inhibited testosterone-induced cell proliferation [78]   
MDA-MB-231       In vitro Reduced cell growth, disrupted mitochondrial [85] 
membrane potential   
MDA-ERalpha7,       In vitro  Retarded NF-kB-dependent reporter gene expression [89] 
MDA-MB-231    and reduced expression of RhoC and RhoA protein  
  MCF-7        In vitro Inhibited cell growth and induced apoptosis  [84] 
MCF-7, MDA MB-231,      In vitro Reduced VEGF, inhibited angiogenesis  [86]  
MCF-10A 
 
Cervical cancer 
HeLa        In vitro Up-regulated the expression of IGFBP7 and   [129] 
inhibited AKT/mTOR pathway          
      
Colon cancer 
  Caco-2        In vitro Reduced the intracellular ROS and malondialdehyde  [143] 
levels, and elevated the SOD activity    
  HT29, HCT116       In vitro Decreased the expression of VEGF and  [45] 
pro-inflammatory cytokines  
  AOM-induced ACF rats      In vivo Reduced AOM-induced colon cancer in rats,  [99] 
through its potent antioxidant activities 
  HT29        In vitro Inhibited phosphorylation of PI3K/AKT and mTOR,  [58] 
and promoted miR-126 expression. 
AOM-induced ACF rats      In vivo Suppressed mRNA and protein expression of [58] 
NF-κB and VCAM-1  
  DMH-induced rat s      In vivo Suppressed Wnt signaling     [49]   
Caco-2        In vitro Reduced the expression of cyclins A and B1,  [98] 
 bcl-XL and regulated caspase-9 and -3 
  HT-29        In vitro Terminated TNF alpha-induced AKT activation  [55]   
HT-29, HCT116,       In vitro Reduced proliferation of tumor cells  [96]   
SW480, SW620           
 AOM-induced ACF rats      In vivo Elevated the expression of PPAR gamma protein [100] 
   
Leukemia 
  K562        In vitro Inhibited tumor cell proliferation via cell cycle arrest [68] 
  CCRF-CEM, MOLT-3,      In vitro Decreased ATP levels, activated caspase-3 and  [42] 
HL-60, THP-1    induced apoptosis   
 [42][42][42][42][42] 
Jurkat, SUP-B15, MOLT-3    In vitro Reduced tumor cell growth and also induced  [144] 
CCRF-CEM, HL-60,    apoptosis  
THP-1, K562, KG1a 
K562        In vitro Reduced tumor cell growth   [40]  
HL-60        In vitro Inhibited proliferation of tumor cells  [103] 
  
Liver cancer 
HepG2                                     In vitro Suppressed cell growth and antioxidative effects [108] 
HepG2        In vitro Upregulated the level of Caspase-3/9 and cyt-c, and [106] 
     cell cycle arrest at S-phase 
  DENA induced-rat       In vivo Reduced the expression of heat shock protein 70 [56] 
   hepatocarcinoma      and 90, COX-2 and NF-κB               
DENA induced-rat      In vivo Elevated nuclear factor E2-related factor 2 (Nrf2) [63]   
hepatocarcinoma 
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TCA exposed rats   Antioxidant and protective effect against   [107] 
carcinogenic TPA induced oxidative injury 
Lung cancer  
A549        In vitro Down-regulated VEGF, MMP-2 and MMP-9 [41] 
 A549, H1299, LL/2      In vitro Cell cycle arrest in G2/M phase, reduced ROS,  [43] 
MMP-2 and MMP-9    
A549        In vitro Inhibited tumor cell proliferation   [109]   
A549        In vitro Suppressed tumor growth    [31]  
[B(a)P], NTCU induced      In vivo Inhibited regulation of NF-κB and, mTOR pathway [59]  
lung tumor     Suppressed the phosphorylation of Akt, MAPK 
 A549          In vitro Suppressed the NF-κB DNA-binding activity  [50] 
  
Multiple myeloma 
A375, B16F10       In vitro Down-regulated VEGF, MMP-2 and MMP-9 [41] 
 B16F10 - C57BL/6 mice      In vivo Inhibited pulmonary lung metastasis   
  
KMS26, MM1S and U266     In vitro  Upregulated PPARγ mRNA expression,  [41] 
     blocked cell cycle in G0/G1 phase     
  U266       In vitro Increased loss of mitochondrial membrane potential,   [127] 
cell cycle arrest, and reduced expression of MMP 
Ovarian cancer 
  A2780        In vitro Inhibition of β-catenin signaling pathway  [66] 
  SKOV3        In vitro Inhibited tumor cell proliferation   [109] 
  SKOV3        In vitro Inhibited tumor cell proliferation   [31]  
Pancreatic cancer 
  PANC-1, AsPC-1     In vitro Suppressed the rate of cell proliferation  [130]  
Prostate cancer 
           DU145, PC3, TRAMP-C1    In vitro          Upregulated the Bax/Bcl-2 expression ratio     [119]               
           PC-3 LNCaP, and BPH-1    In vitro          Increased the expression of caspases-3 and -8     [113]                       
  PC-3        In vitro Inhibited tumorous growth   [31]  
LNCaP, PC-3, DU145      In vitro Elevated Bax/Bcl-2 ratio and also caspase 3,  [46] 
      reduced cyclin D1, cdk1  
TRAP model       In vivo Suppressed tumor progression and induced apoptosis [46] 
       by caspase 3 activation 
LNCaP        In vitro Inhibited proliferation of tumor cells  [11]                              
22RV1, LNCaP       In vitro Reduced testosterone, DHT, DHEA,  [116] 
androstenedione, androsterone, and pregnenolone  
PTEN knockout mouse      In vivo Reduced the level of serum steroids   [116]  
PC3, C4-2, ARCaPM      In vitro Inactivated survivin and Stat3   [118] 
          In vivo Inhibited tissue expression of survivin and induced 
apoptosis  
  LNCaP-AR, DU145,       In vitro Inhibited tumor cell growth   [114] 
  22RV1 
  SCID Mice       In vivo Inhibited the growth of tumorous xenograft tissue [114]  
  T24        In vitro Activated pro-capspase-3, -8 and -9 , also increased  [75] 
Bax/Bcl-2 ratio 
 DU-145, PC-3       In vitro Induced cell cycle arrest and apoptosis  [115] 
 PC-3, PLS10       In vitro Decreased secretion of MMP-2, inhibited collagenase [52] 
IV activity  
 PC3        In vitro Inhibited cell proliferation and induced apoptosis [145] 
 DU145, PC3, LNCaP      In vitro Inhibited the CXCR4/SDF1α chemotaxis axis and  [70] 
decreased oncogenic miRNAs    
DU145        In vitro Dys-regulated proteins participated in cytoskeletal  [110] 
functions, anti-apoptosis, proteasome activity,  
NF-κB signaling etc.  
 TRAMP model       In vivo Suppressed IGF-I/Akt/mTOR pathways  [14] 
 LNCaP        In vitro Promoted intrinsic apoptosis via a caspase-dependent [112] 
pathway    
 LAPC4, 22RV1       In vitro Increased JNK phosphorylation, and reduced  [60] 
activation of Akt, mTOR  
 LAPC4 xenograft model      In vivo Suppressed NF-κB and cell viability of tumor cells [61]             
 LNCaP-AR, DU-145      In vitro Down-regulated the gene expression involved in  [117] 
androgen synthesis  
LAPC4 xenograft SCID      In vitro Inhibited cell growth and proliferation  [111] 
AC
CE
PT
ED
 M
AN
US
CR
IPT
28 
 
mice  
 LNCaP, HUVEC       In vivo VEGF peptide levels and HIF-1alpha expression [111] 
 were decreased   
  LAPC4, 22RV1       In vitro Decreased Igf1 mRNA expression   [60] 
 LAPC4 xenograft SCID mice In vivo Suppressed tumor growth    [114] 
 PC3        In vitro Inhibited proliferation of tumor cells  [48] 
 CWR22Rnu1 xenograft      In vivo Reduced tumor growth    [48]  
 athymic nude mice 
 PC-3         In vitro Reduced tumor proliferation and invasion   [146] 
Skin cancer 
  2-stage mouse skin cancer      In vivo Reduced the levels of phosphorylated ERK1/2, JNK1 [125] 
       decreased NF-κB/p65, IKKα and IκBα  
phosphorylation 
SKH-1 hairless mouse      In vivo Suppressed UVB radiation-induced carcinogenesis [124]  
       and increased expression of p53 and p21   
  NHEK        In vitro Suppressed UV-B-mediated phosphorylation of  [126] 
MAPK and inhibited p38 protein    
TPA induced cancer in            In vivo Inhibited TPA-induced phosphorylation of ERK1/2, [123] 
CD-I mice    p38, and JNK1/2, inactivated NF-κB and IKKα, and  
inhibited phosphorylation of IκBα 
 
------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
ABBREVIATIONS 
ACF, Aberrant crypt foci; ATP, Adenosine triphosphate; AOM, Azoxymethane ;  [B(a)P], Benzo(a)pyrene; 
BAD, Bcl-2-associated death promoter protein; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; 
CDK1, Cyclin-Dependent Kinase 1; CXCR4, Chemokines receptor type 4; DENA, Diethylnitrosamine ; 
DHEA , Dehydroepiandrosterone; DHT, Dihydrotestosterone; DMH, 1,2-dimethylhydrazine 
dihydrochloride; ERE, Estrogen response elements; HIF-1, Hypoxia-inducible factor 1; IGF-1, Insulin-like 
growth factor 1; JNK , Jun amino-terminal kinases; MAPK, Mitogen-activated protein kinases; MCP-1, 
Monocyte chemoattractant protein-1; MIP, Macrophage Inflammatory Proteins; MMP, Matrix 
metalloproteinase; mTOR , Mechanistic target of rapamycin; Nrf2, Nuclear factor E2-related factor 2; 
NTCU, N-nitroso-tris-chloroethylurea; PI3K,  Phosphatidylinositol 3,4,5-trisphosphate; PPAR, Peroxisome 
proliferator-activated receptor; RhoC, Ras homolog family member C; ROS, Reactive oxygen species; 
SCID, Severe combined immunodeficient mice; SHIP-1, Inositol 5'-phosphatase; Sp, Specificity protein; 
STAT3, Signal transducer and activator of transcription 3; TGF-β, Transforming growth factor-β ; TNF-α,  
Tumor necrosis factor-α; TRAP, Transgenic rat for adenocarcinoma of prostate model; VCAM-1, Vascular 
cell adhesion molecule 1; VEGF, Vascular endothelial growth factor.  
 
 
Table 2: Studies on the potential of pomegranate in the prevention and treatment of cancer (clinical studies) 
------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Cancer type  Dose  Pts      Phase Clinical outcome   Reference 
------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Prostate cancer  -  183         -  No significant elongation in PSADT [134] 
Breast cancer  8 ounces/day -         -  Decline in estrone and testosterone  [32]  
   3 weeks 
Colorectal cancer  900 mg/day, 52         -  Significant levels of EA derivatives, [97] 
   15 days     urolithins were formed in colon tissues  
Prostate cancer  100mg, thrice/ 199         -  Rise in PSA    [132] 
   day, 3-6months 
Prostate cancer  2 tablets/day, 70         -  Accumulation of urolithins,  [135] 
   4 weeks     reduced oxidative stress    
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Prostate cancer  1 or 3 g,  144        II  PSADT increased in 43% of patients, [137]  
18 months    13% showed decline in PSA 
Prostate cancer  200 mL/day, 63         -  Traces of urolithin A and B,  [131] 
            3 days     glucuronide, dimethyl ellagic acid   
Prostate cancer   -  48        II  Significant prolongation of PSADT  [133]  
------------------------------------------------------------------------------------------------------------------------------------------------------------- 
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